{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.77","value":"79.86"},{"groupId":"OG001","spread":"5.42","value":"96.82"}]}],"title":"Post-Operation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.52","value":"80.55"},{"groupId":"OG001","spread":"13.61","value":"88.89"}]}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Patient satisfaction was assessed with a pain control questionnaire. The participants were asked questions about their pain satisfaction over the last seven days. The pain control questionnaire was scored from 0-100, with smaller values indicating poor pain control satisfaction and larger values indicating excellent pain control satisfaction.\n\nThis outcome was assessed at post-surgery and end of treatment for up to 5 months","dispersionType":"Standard Deviation","groups":[{"description":"Patients received celecoxib PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nCelecoxib: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Celecoxib Arm"},{"description":"Patients received placebo PO or via feeding tube BID starting 1 to 7 days prior to surgery and continued until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.\n\nPlacebo: Given PO or via feeding tube\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Placebo Arm"}],"paramType":"MEAN","populationDescription":"One participant on the Celcoxib Arm was not evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"post-surgery (up to 29 days from surgery) and end of treatment (up to 5 months from surgery)","title":"Assessment of Overall Pain Control and Management for Patients on Celecoxib Compared to Placebo - Pain Control Questionnaire.","type":"SECONDARY","unitOfMeasure":"score on the pain control questionnaire"}